Previous close | 14.95 |
Open | N/A |
Bid | 0.00 |
Ask | 0.00 |
Strike | 160.00 |
Expiry date | 2024-08-16 |
Day's range | 14.95 - 14.95 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Shares of Novo Nordisk (NVO) and Eli Lilly (LLY) are sliding after Roche (ROG.SW, RBO.PA) reported promising early-stage trial data from its weight-loss pill. Yahoo Finance Senior Reporter Anjalee Khemlani breaks down the trial results and how the medication may disrupt the current state of the weight-loss drug market as GLP-1 drugs like Novo Nordisk's Ozempic and Eli Lilly's Mounjaro face record demand. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Melanie Riehl
The tech-heavy Nasdaq Composite (^IXIC) and S&P 500 (^GSPC) are taking hits leading into the final trading hour of Wednesday, July 17, in connection to a selloff by semiconductor companies. Julie Hyman and Josh Lipton bring on the leading experts and market strategists to talk about where the market is headed and how US-China trade relations could impact growth. Yardeni Research President Ed Yardeni joins the program to discuss movements in small and mid cap stocks, touching on which direction tech sector trends could move in based on the Federal Reserve's commitment to interest rate cuts. KraneShares Managing Director David Adelman, who also served as the US ambassador to Singapore, comments on the role stricter US export controls could have on pushing China to possibly "accelerate... development of its ecosystem." Wedbush Securities SVP of equity research Matt Bryson believes the US-China trade policies won't have much effect on chipmakers like Nvidia (NVDA). Other top trending tickers on the Yahoo Finance platform include Tesla (TSLA), Charles Schwab (SCHW), JB Hunt Transport Services (JBHT), and Johnson & Johnson (JNJ) after the pharma giant reported a second-quarter beat on earnings estimates. This post was written by Luke Carberry Mogan.
After previously discounting a twice-daily version of its weight loss drug due to patients having difficulties tolerating it, Pfizer Inc (NYSE: PFE) moved forward with the once-daily version. On Thursday, Pfizer revealed it will begin studies to evaluate the optimal dose of its weight lose pill during the second half of the year. With the new formulation, Pfizer continues its attempt to catch up to Eli Lilly and Company (NYSE: LLY) and Novo Nordisk (NYSE: NVO) who are currently dominating the we